The changing nature of the clinical syndrome of ARF If I were asked to identify one clinical situation where renal replacement therapy tends to fail and a therapeutic breakthrough is most urgently needed, I would name, without hesitation, acute renal failure (ARF) in critically ill patients. Despite the widespread availability of dialytic and intensive care technology, mortality is distressingly high in critically ill patients with ARF and has remained at a level greater than 50% over the last 50 years. There are multiple factors which may explain this phenomenon. The most important is probably the change in the clinical characteristics of patients susceptible to ARF who can be kept alive through medical progress, but who would previously have died before developing ARF. Hemodialysis can be lifesaving in some patients, but its impact on outcome may be overridden by the increased severity of the underlying illness in others. The presence of non-renal organ failure, pre-existing chronic illness and the acuity of the disease underlying ARF all have a major impact on the outcome of critically ill patients with ARF. There is no doubt that the severity of the renal injury is another important factor. A number of studies have demonstrated that the need for renal replacement therapy is associated with a poorer prognosis, and that the level of the residual golmerular filtration rate has been found to be a strong predictor of survival. Simply put, the worse the kidney function, the lower the urine flow rate, the higher the rate of mortality (1) (2) (3) (4) .
The ability to assess these variables objectively is critically important in order to make accurate comparisons of outcome of ARF. Most investigators now use the APACHE II score, which takes into account the age of the patient, pre-existing chronic disease and the acute physiology score of the patient. However, the predictive value of the APACHE II score is poor in patients with septicaemia, preexisting lung disease or more than one chronic health problem. The usefulness of the APACHE II score in estimating the progress of ARF patients and for comparing outcomes between different ARF populations has been shown by most, but not by all, investigators. Nevertheless, there is a need for further refinement of the APACHE II score when it is applied to ARF patients. The failure to outline more accurately the characteristics of the patients studied makes it difficult if not impossible to interpret the published results (5, 6) .
Dialytic therapy of ARF: what we need to find out
The persistently high mortality of ARF in critically ill patients leaves no room for complacency in the management of ARF as major clinical questions posed decades ago remain unanswered (7) .
Why do these patients die?
Before the development of dialytic and filtrative techniques, the most common causes of death in patients with ARF were progressive uremia, hyperkalemia, and complications of volume overload or hemorrhagic diathesis. With the advent of dialysis, the most common causes of death are now sepsis, cardiovascular and pulmonary dysfunction (8) . In critically ill patients, septicaemia is the most serious complication precipitated by ARF, which occurs in 30 to 70% of cases and accounts for a significant proportion of deaths (2) .
The high frequency of infections is usually multifactorial in origin and reflects a) repeated breaches of mucocutaneous barriers, b) defective host immunity due to persistence of preuremia even in treated patients with ARF and c) the hypercatabolic state of ARF and of the dialytic therapy which is usually aggravated by inadequate nutritional support. Recent studies revealed that dialysis as traditionally described for ARF (i.e. intermittent hemodialysis) is grossly inadequate applying the standard of care in chronic dialysis and that there are significant differences between the described and delivered dialysis dose in ARF (9) . Recently an interesting observation was reported by Paganini et al (10) who were able to show that in 58 consecutive ICU patients treated with intermittent hemodialysis survivors had higher mean KW urea than non-survivors (1.09 vs. 0.89). While earlier studies suggested a trend toward better survival in patient groups dialyzed more intensively, Gillum et al (11) failed to detect substantially significant differences in the outcome of two groups of patients with either medical or surgical/trauma induced ARF, receiving two different intensities of intermittent hemodialysis (IHD) with cuprophane membranes. There was, however, a disturbing trend toward higher mortality in the surgical/trauma subset who were more intensively dialysed. Carefully designed prospective studies using current dialysis techniques (volumetrically controlled ultrafiltration, sodium profiles, biocompatible membranes) that minimise side effects from the dialysis procedure itself need to be carried out to test the hypothesis that increasing the intensity of the delivered dialysis dose will lessen uremic complications and improve outcome. However, it is safe to state that the widespread old nephrological aphorism "No ARF patient has ever died because of ARF but with ARF" is obsolete.
Does dialytic therapy itself have a negative impact on the outcome of critically ill patients with ARF?
The goals of acute dialytic therapy differ substantially from those in end-stage renal disease. In the treatment of ARF, there is little risk of long-term consequences of impaired or absent kidney function, such as metabolic bone disease or dialysis-related amyloidosis. The therapeutic goals of acute "interventional" renal replacement therapy are to replace excretory kidney function with as little disruption of vital organs as possible to allow functional recovery of the kidneys. The theoretical concern that IHD may impact on morbidity and mortality of ARF patients is based on a variety of observations. The increased susceptibility to bacterial infections observed in patients with ARF may relate in part to the bioincompatibility of the dialyser membrane used. In vitro studies have clearly shown that uremia and hemodialysis membranes have separate but additive effects on circulating neutrophils (12) . The commonly accepted hypothesis is that these cells are activated as a result of ARF or by its treatment with biocompatible (extensive complement or cell activating) membranes and are later deactivated or relatively hyporesponsive to subsequent stimuli. These effects may be due to alternations in cell surface receptors, signal transduction mechanisms and/or intracellular products which prevent them from mounting the proper response. Furthermore, repeated changes in leukocyte function and kinetics during bioincompatible hemodialysis combined with intestinal hypoperfusion after major surgery or trauma may alter the intesti-360 nal mucosal barrier and enable intestinal gram-negative bacteria to enter the blood-stream (13) . The association of bioincompatible hemodialysis membranes with a higher incidence of lethal infections is supported by studies in patients with end-stage renal disease maintained on regular hemodialysis (14) (15) (16) (17) . Secondly, functional recovery from ARF may be markedly delayed in critically ill patients with ARF receiving IHD. The process of IHD may acutely damage the kidneys. This concept is supported by the measurement of glomerular filtration rates (1) which frequently decline after initiation of IHD. Furthermore exacerbated enzymuria (18) and the documentation of fresh foci of tubular necrosis in kidney biopsies obtained from patients with dialysis dependent ARF (19, 20) indicate tubular injury in patients with ARF when IHD is initiated. Recurrent episodes of hypotension caused by ultrafiltration as well as complement and cell activation induced by blood-membrane interactions may account for the prolongation of ARF.
Clinical studies of bioincompatibility in patients with ARF
For the methods of blood purification used in ARF it is very important, but also most difficult to identify sources of bioincompatibility. This is due to several factors. In critically ill patients many of the patterns of bioincompatibility reactions ressemble those reactions caused by the circumstances precipitating ARF. Patients do not adapt to, but on the contrary appear particulary susceptible to, cessation of renal function and its complications as well as to the repeated exposure to bioincompatible membranes. This leads to the recurrent generation and release of proinflammatory molecules which induce and maintain multiple organ failure in these patients. Evidence -based rather than empirical decisions are surely needed for the treatment of ARF. Prospective randomized controlled clinical trials and meta-analyses are considered to be the most reliable instruments to produce scientific evidence needed to guide clinical practice (21) . There is a consensus that any intervention trial in ARF should consider more than one end-point such as requirement for dialysis (frequency and duration), mortality and causes of death, recovery of renal function or permanent dysfunction requiring dialysis etc (22) . Based on the hypothesis that cuprophane type membranes may adversely affect the recovery of critically ill patients from ARF, several clinical trials were performed recently, which were either prospective-randomized or retrospective in nature and either single -or multi-centerstudies (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Unfortunately, a number of studies were primarily designed to answer other questions relevant to ARF and had only one endpoint. In one prospective randomised study, Schiffl and colleagues (23) examined whether the generation of inflammatory mediators by bioincompatible membranes had an adverse effect on the outcome of ARF. Fifty-two critically ill patients with postoperative acute tubular necrosis, similar in age, severity of ARF and APACHE II score were randomised to receive hemodialysis with either cuprophane or polyacrylonitrile membranes. Cuprophane membranes induced intensive activation of the complement system, as demonstrated by the monitoring of C3a and leukotriene B4 serum concentrations. The group dialysed with cuprophane membranes had a lower survival rate, a higher mortality rate from sepsis, required more dialysis sessions (12 vs. 9) and delayed recovery of renal function compared with the polyacrylonitrile group. In a prospective randomised comparison of 72 critically ill patients with different etiologies of ARF, Hakim et all (26) also have shown that dialysis with the more biocompatible polymethylmethacrylate membrane (PMMA) compared to the cuprophane membrane, resulted in a higher rate of recovery of renal function, a more rapid recovery of renal function (as assessed by the number of dialysis treatments needed) and a better patient survival. In the study by Hakim et al (26) the benefits observed were particularly evident in individuals who had non-oliguric renal failure prior to the initiation of hemodialysis. In these patients renal blood flow is generally higher, which may render the kidneys more susceptible to activated complement products and free oxygen radicals in the circulation. In addition, the results of a multicenter prospective randomised trial (25) , in which the largest group of patients so far (more than 150) was randomised to dialysis with more biocompatible membranes (low flux polysulfone or PMMA) or cuprophane membranes, showed a clear benefit of more biocompatible membranes with regard to duration of the stay in the ICU or hospital, enhanced recovery of renal function, as well as improved patient survival in previously nonoliguric patients. The French Study Group on Acute Renal Failure (30) conducted a prospective 6 month trial in 20 multidisciplinary intensive care units to assess the prognosis of patients hospitalized with ARF due to sepsis. The results of these investigations demonstrated a significant decline in mortality by dialysing patients with biocompatible synthetic membranes rather than with bioincompatible cuprophane membranes.
The difference in mortality remained significant if the mortality rate was adjusted for septicaemia. In a prospective trial comparing continuous renal replacement therapy to IHD, Mehta et al (33) assessed the effect of membrane bioincompatibility on the outcome of ARF (ICU/hospital mortality and renal recovery) in ICU patients treated with IHD. These authors analyzed the records from 160 patients who received IHD alone and stratified them based on the biocompatibility of the membrane into low (cuprophane), medium (cellulose acetate, hemophane, PMMA) and high biocompatibility (polysulfone or polyacrylonitrile). The treatment groups were similar with respect to the etiology of ARF and to the prevalence of oliguria at initiation of dialysis. However, the patient groups were significantly different with respect to APACHE II scores (low biocompatibility 99.6, medium biocompatibility 80.6, high 71.3). Taken as a whole, there was a strong relationship between the type of membrane used and the mortality rate. Splendiani et al (34) published a retrospective study covering the period between 1983 and 1984 in 5 regions of central Italy. The records of 105 patients with ARF seen in 9 nephrology units were analyzed. Eighteen patients (17%) received hemodialysis with the biocompatible polyacrylonitrile membrane, the other 87 patients (83%) were treated by IHD with the bioincompatible cuprophane membrane. The data of this analysis indicate that hemodialysis with polyacrylonitrile improved the prognosis of patients with ARF (lower mortality) and shortened the length of dialysis treatment. By contrast, only one study failed to demonstrate a reduction in mortality and an improvement of recovery of renal function in critically ill patients with ARF. Kurtal et al (27) assigned 57 patients with dialysis-dependent ARF either to treatment with cuprophane (25 patients) or polyamide (32 patients). In addition to the assignment of consecutive rather than balanced pairs of patients, the study groups differed in the most frequent and severe etiology of ARF. Ten of 25 patients (40%) receiving polyamide, but only 7 of 32 patients (22%) of the cuprophane group had hypotension as the cause of ARF. A meta-analysis of the published trials investigating the effects of complement and cell-activating dialyzer membranes on the outcome of ARF would clearly demonstrate a significant influence of bioincompatibility. Differences in co-morbidity between study groups could possibly explain the conflicting results observed in some studies.
Comparisons of membranes with a different degree of biocompatibility
There are a variety of membranes with a small complement-activating potential, encompassing cellulose acetate, hemophane or low-flux polysulfone. They are collectively called medium biocompatible membranes. By contrast, regenerated cellulose membranes are called bioincompatible. Whether or not the effects of the biocompatibility of dialysis membranes on the outcome of ARF are "all or nothing" phenomena i.e, whether they can be demonstrated only with cuprophane versus synthetic membranes or whether they may be even noticeable comparing medium biocompatible with noncomplement activating membranes remains to be demonstrated. Metha et al (33) noted a higher mortality with membranes of medium biocompatibility (PMMA, low-flux polysulfone or celluloseacetate) as compared with synthetic membranes (polysulfone, polyacrylonitrile). However, the two study groups differed in the severity of the APACHE II score. Gastaldello et al (31) compared a cellulose diacetate membrane with medium complement-activating potential with low-flux polysulfone (medium biocompatible) or high-flux polysulfone (high biocompatibility) in ICU patients with ARF requiring IHD. One hundred and thirty-four patients were stratified at the initiation of IHD according to a disease severity score (SC, APACHE III) and randomly assigned to one of the membranes. The results did not reveal significant differences in survival or recovery of renal function among the three treatment groups. Another trial was performed by Assouad et al (32) , who randomized 51 patients with ARF requiring IHD either to cellulose acetate or PMMA. There was no difference in age, sex, ethnic background, cause of ARF or APACHE III score between the two study groups. Numerically, more patients in the cellulose acetate group recovered from ARF, fewer cases developed oliguria, fewer remained on dialysis, but the differences were not statistically significant because of the limited sample size. In addition, the Madrid Acute Renal Failure Group (28) studied in a prospective trial the incidence, etiologies and clinical features of ARF in the Spanish Capital. 748 cases of ARF were identified and 207 patients needed dialysis. In 134 patients who received IHD the type of membrane was documented. 84 patients were treated with cellulosic membranes (not further specified), the remaining 50 patients underwent hemodialysis with synthetic membranes. The results suggested that mortality was similar with modified cellulosic and synthetic membranes.
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Morbidity of bioincompatibte tHO in ARF
Biocompatibility reactions caused by dialyzer membranes may affect morbidity in critically ill patients with ARF by different pathologic mechanisms. There is circumstantial evidence that bioincompatible IHD delays recovery of renal function in patients with ARF (23, 26, 34 ). The consequences of prolonged acute oliguric failure affect the organism as a whole. The adverse effects may involve cardiac function, oxygenation, neurologic status, coagulation and the ability of the individual to combat infection -the major problems that brings patients to the ICU. There are a number of reports that even mild to moderate ARF may increase mortality of critically ill patients (35) , and there is no doubt that the persistence of bioincompatibility reactions contributes to the high mortality in patients treated with bioincompatible IHD. The single most important cause of mortality in critically ill patients with ARF is infection, which is aggravated by bioincompatibility. Leukocytes activated by the complement -activating cellulosic membranes increase the susceptibility to infections in patients with ARF, because these cells -once activated -have been shown to be less responsive to chemotactic agents and to have reduced phagocytic activity (36) . Moreover, the higher incidence of gram-negative sepsis in critically ill patients with ARF suggests that bacteremia due to gram negative bacteria is favoured by postoperative ischemic alterations of the gastrointestinal barrier and by recurrent neutropenia during IHD (24) . These changes occur in the combination of bioincompatible IHD and ARF and have been demonstrated in the clinical setting of cardiopulmonary bypass and open heart surgery (37) . Malnutrition, in part evident through hypercatabolism, is associated with reduced survival in critically ill patients with ARF. There is emerging evidence that not only the hemodialysis procedure per se may be responsible for increased protein catabolism via loss of aminoacids, peptides and glucose but also that the biocompatibility of the membrane, in particular, the elaboration of cytokines from cells activated after contact with bioincompatible surfaces of the dialyzer membranes, contributes to this process (38) . Finally acute cardiopulmonary morbidity in critically ill patients with ARF requiring hemodialysis may have multiple cause but can present at least in part as membrane derived severe hypotension or hypoxaemia.
Cost of treatment of ARF in critically illpatients
Critical care medicine and intensive care units provide technically advanced, yet expensive, treatment. Costeffectiveness calculations have to consider three criteria: a) Recently published prospective studies in Europe (28, 39, 40) , have revealed an incidence of severe ARF of 170 to 210 cases per million population, the need of dialysis in ARF ranged from 22 patients per million population (pmp) to 85 cases pmp. b) A number of reports found that the mean stay of critically ill patients with ARF requiring dialytic therapy in the ICU was in the range of 8 to 25 days and the mean total hospital stay until discharge ranged from 37 to 58 days. c) The difference between cellulosic (coprophane) membranes and synthetic membranes is between 20 and 30$ US. Bearing this in mind, it seems reasonable to state that the dialyzer costs add little if any to the "astronomic" costs of treating the surviving patients with ARF by dialysis. If one were asked to perform a metaanalysis of prospective studies comparing cuprophane membranes with synthetic membranes one would find that at least 10% of any critically ill patient population is saved by the right choice of membrane. Surprisingly, a recent propagist of the cuprophane membrane stated that for the difference between the costs of dialyzers with extreme differences of biocompatibility we can buy "10-12 new highly sophisticated dialysis machines" (41) .
Scientific progress or corporate interest
Despite extensive scientific evidence -ranging from laboratory investigations and animal experiments to prospective randomised controlled clinical trials and clinical observations after renal transplantation, which substantiates the causal relationship between the outcome of critically ill patients with ARF and the adverse reactions caused by bioincompatibility in these patients, manufacturers and distributors of the cuprophane membrane started a misinformation campaign. They prefer to try to discredit the data rather than reformulate their products. In addition, their propagists failed to provide scientifically sound data of their own (41) (42) (43) (44) . The authors of this editorial have entered into scientific debate (45, 46) with one of the more active members of the propagist group, whose expertise 1) the actual spellings are: Procrustes and Gauss lies in the treatment of chronically ill renal patients rather than in the care of critically ill patients with ARF and who has not been actively involved in related research. However, our replies have prompted a withdrawal from scientific debate and entry into the realm of personal crusade. The said propagist even resorted to the dead "Procustres"') and Gaus?" (sic) to strengthen the "argument" and interestingly enough was allowed to publish the same article in two separate journals (47, 48) . The tactics used over bioincompatibility are much the same as those used by the same membrane researchers in the discrimination of the re-use of dialyzers (49, 50) . However, the latter campaign failed and the same seems to be true for the biocompatibility issue. A recent survey in USA nephrologists revealed that the majority of physicians used synthetic membranes in the dialytic therapy of ARF (51).
CONCLUSIONS
The continuing high mortality of critically ill patients with ARF remains a challenge to intensive care physicians and nephrologists caring for these patients. There is no place for nihilism in the treatment of ARF, and there are a number of areas which may lead to further progress (intensity of dialysis, nutrition, evolution of continuous treatments). The routine use of biocompatible membranes in the therapy of ARF is not a therapeutic breakthrough, but adds some progress to improve the devastating outcome of these patients (52) . In the management of ARF, every advance is important. Savings are important when budgets are cut, but what we really need is to safeguard the quality of care of patients with acute renal faillure. What seems cheaper at first glance may turn out to be more expensive in the end. 
